A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis
Study sponsor: Vanda Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-04-23Actual
Enrollment · participants59Actual
Source updated2025-09-15Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.